Mylan and TB Alliance Collaborate to Commercialize Pretomanid in Two Combination Regimens for Tuberculosis

 Mylan and TB Alliance Collaborate to Commercialize Pretomanid in Two Combination Regimens for Tuberculosis

Mylan and TB Alliance Collaborate to Commercialize Pretomanid in Two Combination Regimens for Tuberculosis

Shots:

  • Mylan to get manufacturing & commercialization rights of pretomanid in BPaL regimen (bedaquiline, pretomanid and linezolid for 6-9 mos.) for XDR & MDR-TB. Janssen to hold the rights for bedaquiline (Ex- DS-TB) and linezolid is available from multiple manufacturers, including Mylan
  • TB Alliances has also licensed Pretomanid to Mylan for DS & MDR-TB and sublicensed bedaquiline for DS-TB only in BPaMZ regimen (bedaquiline, pretomanid, moxifloxacin and pyrazinamide for 4-6mos.)
  • Pretomanid as part of the BPaL regimen is under FDA & EMA review. Mylan gets a non-exclusive & exclusive license to commercialize Pretomanid in low-& middle -income & high-income markets respectively. Janssen will retain exclusive rights to market bedaquiline as part of the combination therapy for MDR-TB

Click here to read full press release/ article | Ref: Mylan | Image: WV News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post